Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

LIFELINE MEDICAL LABORATORY INCORPORATED

NPI: 1083189088 · NORTH HOLLYWOOD, CA 91601 · Clinical Medical Laboratory · NPI assigned 10/05/2018

$55K
Total Medicaid Paid
47,524
Total Claims
46,702
Beneficiaries
9
Codes Billed
2023-04
First Month
2024-11
Last Month

Provider Details

Authorized OfficialROBLES, JUAN (OWNER)
NPI Enumeration Date10/05/2018

Related Entities

Other providers sharing the same authorized official: ROBLES, JUAN

ProviderCityStateTotal Paid
PEPINO HEALTH GROUP INC SAN SEBASTIAN PR $188K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2023 11,529 $24K
2024 35,995 $31K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 5,905 5,806 $33K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 7,557 7,428 $13K
87150 630 621 $2K
82043 8,069 7,925 $1K
82436 8,166 8,022 $1K
87631 631 622 $1K
84300 8,176 8,032 $1K
84133 8,168 8,024 $1K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 222 222 $521.03